Grant: Master's Award: Canada Graduate Scholarships
University of British Columbia
$17,500.00
Levonorgestrel Intrauterine Device and Risk of Ovarian and Breast Cancers
EF 2022-23
Résumé
Nearly 40% of all cancers in women are breast or ovarian cancers. While breast cancer is far more prevalent and comprises about 37% of female cancers, ovarian cancer has a very low 5-year survival rate. Ovarian and breast cancers are uniquely linked in that certain factors can affect the risk of both differently. For example, oral contraceptives (OCPs) may increase breast cancer risk but are associated with significant and large reductions in ovarian cancer risk. While OCPs were historically, and continue to be, a popular contraception choice, other methods are quickly becoming equally popular, such as the levonorgestrel intrauterine device (LNG-IUD). The LNG-IUD is a long-acting form of contraception which is implanted into the uterus and releases the hormone levonorgestrel. Given this increasing popularity, understanding the potential association of the LNG-IUD with cancer is incredibly important. Large shifts in the use of contraception with different effects on risk for breast and ovarian cancers can result in future population level shifts in incidence of these cancers. We will be using population-based health data to investigate the association between the LNG-IUD and ovarian and breast cancer risk. Understanding these risks will allow clinicians to comprehensively counsel patients on the ways their contraceptive choices could influence future cancer risks, so that they can make informed decisions about their reproductive health.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
British Columbia, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
486232
Name
Shore Abigail M
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Levonorgestrel Intrauterine Device and Risk of Ovarian and Breast Cancers
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Breast Cancer; Cancer Prevention; Hormonal Contraception; Levonorgestrel Intrauterine Device; Ovarian Cancer
Abstract
Nearly 40% of all cancers in women are breast or ovarian cancers. While breast cancer is far more prevalent and comprises about 37% of female cancers, ovarian cancer has a very low 5-year survival rate. Ovarian and breast cancers are uniquely linked in that certain factors can affect the risk of both differently. For example, oral contraceptives (OCPs) may increase breast cancer risk but are associated with significant and large reductions in ovarian cancer risk. While OCPs were historically, and continue to be, a popular contraception choice, other methods are quickly becoming equally popular, such as the levonorgestrel intrauterine device (LNG-IUD). The LNG-IUD is a long-acting form of contraception which is implanted into the uterus and releases the hormone levonorgestrel. Given this increasing popularity, understanding the potential association of the LNG-IUD with cancer is incredibly important. Large shifts in the use of contraception with different effects on risk for breast and ovarian cancers can result in future population level shifts in incidence of these cancers. We will be using population-based health data to investigate the association between the LNG-IUD and ovarian and breast cancer risk. Understanding these risks will allow clinicians to comprehensively counsel patients on the ways their contraceptive choices could influence future cancer risks, so that they can make informed decisions about their reproductive health.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Shore, Abigail M
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~